Page 277 - Drug Class Review
P. 277
Drug Effectiveness Review Project
Alzheimer Drugs Authors: Knapp et al., 1994; 68 Farlow et al., 1995; 86 Knopman et al., 1996; 87 Farlow et al., 1998 88 Country: US Warner Lambert To evaluate the efficacy and safety of high dose TAC over 30 weeks in patients with probable AD Study design: RCT Setting: Outpatients at 33 centers Sample size: 653 placebo tacrine N/A 40-80; 40-60-120; 40-80-120-160 30 6-24; 6-6-18; 6-6-6-12 181 472 Men and women > 50 yrs old with mild to moderate AD and otherwise in good health; met NINCDS criteria for AD with symptoms of AD for 1 year Pa
Final Report Update 1 Adverse Events STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose (mg/d): Duration (weeks): Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
